Aceclidine+Brimonidine combination ophthalmic solution + Placebo + Aceclidine Ophthalmic Solution
Phase 3Completed 0 watching 0 views this week๐ Rising
69
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Presbyopia
Conditions
Presbyopia, Near Vision, Miosis, Eye Diseases
Trial Timeline
Feb 21, 2023 โ Feb 9, 2024
NCT ID
NCT05753189About Aceclidine+Brimonidine combination ophthalmic solution + Placebo + Aceclidine Ophthalmic Solution
Aceclidine+Brimonidine combination ophthalmic solution + Placebo + Aceclidine Ophthalmic Solution is a phase 3 stage product being developed by LENZ Therapeutics for Presbyopia. The current trial status is completed. This product is registered under clinical trial identifier NCT05753189. Target conditions include Presbyopia, Near Vision, Miosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05753189 | Phase 3 | Completed |
Competing Products
14 competing products in Presbyopia
Other Products from LENZ Therapeutics
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Placebo (Vehicle) ophthalmic solutionPhase 3
69
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + VehiclePhase 3
69
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + BrimonidinePhase 3
69
Aceclidine+Brimonidine combination ophthalmic solution + Aceclidine ophthalmic solution + Vehicle Proprietary Ophthalmic SolutionPhase 2
44
PRX-100 + PlaceboPhase 2
44